Gian Luca Araldi, PhD
November 11, 2015
Co-Founder & CEO
Avanti Biosciences Inc.
Back to News & Events
November 11, 2015
Related Stories
WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] => all
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 3934
[post_author] => 4
[post_date] => 2022-09-29 14:55:09
[post_date_gmt] => 2022-09-29 14:55:09
[post_content] =>
Two incubator hubs, CIMIT’s CINTA and NeuroTech Harbor, through the NIH Blueprint MedTech program, are currently seeking proposals from academic and industry applicants who have emerging technologies that aim to improve the diagnosis and/or treatment of nervous system disorders.
A major emphasis of this program is to create opportunities for diverse innovators, including those who have been traditionally underrepresented in the neurotech space.
Program Details:
- Awards up to $500K to help support development toward commercialization.
- Mentorship from experienced commercialization experts
Support to address business, regulatory, clinical, and technical project aspects
Pre-proposals are due no later than October 24th. Learn more and apply: https://blueprintneurotech.org/
[post_title] => Blueprint MedTech Program [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => blueprint-medtech-program [to_ping] => [pinged] => [post_modified] => 2022-12-13 17:03:08 [post_modified_gmt] => 2022-12-13 17:03:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3934 [menu_order] => 18 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 1643 [post_author] => 4 [post_date] => 2015-09-15 18:44:52 [post_date_gmt] => 2015-09-15 18:44:52 [post_content] => Independently documented economic impact: $1.2 Billion Jobs created: 1,125 New corporate revenues: $812 Million Supported additional funding: $238 Million Center for Biotechnology documented economic impact over recent fifteen-year period Perhaps it is numbers like these which best illustrate the success CFB has had on the biotechnology industry and economy. And perhaps they contributed to the redesignation of the CFB as a Center for Advanced Technology for ten years by the New York State Foundation for Science, Technology and Innovation (NYSTAR) as a Center for Advanced Technology (CAT). The New York State redesignation recognizes the impact of the CFB over 30 years driving innovation toward commercial goals and resulting in accelerated product development cycles "from bench to boardroom to bedside." It recognizes the key role played by the CFB in facilitating a regional bioscience innovation ecosystem, collaborating with Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory. The redesignation by New York State validates all of the work we have done over the last 10-year period to create the foundation for exponential growth. We would not have secured the National Institutes of Health REACH award without it, says Clint Rubin, Director of the Center for Biotechnology."The REACH designation represents an $8.1M investment in technology development, commercialization, and new company formation. Visionary's like New York State Senator Kenneth La Valle deserve the credit. They recognized thirty years ago that universities represented a largely untapped pool of innovation and economic potential. Strikingly, it validates and provides the foundation for the new Long Island Bioscience Hub (LIBH), a CFB-led initiative to formally bring these institutions together to foster technology development, commercialization, and new company formation. The LIBH is a bold step made possible by a partnership with the National Institute of Health REACH initiative (Research Evaluation and Commercialization Hub). The NIH award places the CFB in the national spotlight along with other elite institutions. (Read more on the NIH REACH award here) "This redesignation occurs in an interesting and changing environment, where varying elements in the regional, state, and national biotech ecosystem are aligning. There is a confluence of events and issues that are creating a unique opportunity to build the biotech economy in the region and across the State." Commented Diane Fabel, Director of Operations, CFB. "We have learned a lot about the process of moving academic innovation into the commercial sector over time. And there have been such tremendous scientific advances recently that represent new commercial opportunities and life saving technologies. There is still much to learn and do, and it is an incredibly exciting time to be doing it. [post_title] => Center for Biotechnology Redesignated by New York State: 'Unique Time of Change and Growth' [post_excerpt] => The New York State redesignation recognizes the impact of the CFB over 30 years driving innovation toward commercial goals and resulting in accelerated product development cycles from bench to boardroom to bedside. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => center-for-biotechnology-redesignated-by-new-york-state-unique-time-of-change-and-growth [to_ping] => [pinged] => http://centerforbiotechnology.org/new/center-for-biotech-receives-nih-award-to-develop-a-bioscience-hub/ [post_modified] => 2016-03-02 17:48:17 [post_modified_gmt] => 2016-03-02 17:48:17 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1643 [menu_order] => 200 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3338 [post_author] => 3 [post_date] => 2019-08-26 13:59:23 [post_date_gmt] => 2019-08-26 13:59:23 [post_content] => Due to a few technical difficulties, and to accommodate new and/or incoming awardees, NIH is extending the deadline to apply to their NIH Commercialization Accelerator Program (NIH CAP). The new deadline is 11:59 p.m. PDT (Pacific) FRIDAY, September 13, 2019. This is a cost free* customized commercialization (market readiness/growth) program. For 16 years, CAP has provided customized technical/business assistance to companies at different stages, and has a notable track record: 50 acquisitions (including companies acquired by Sony, Zoll, Bruker, BioMarin, Illumina, Takeda, Google, Roche, etc.), 10 IPOs, and more than $1B in 3rd party funding raised. The program features:- world-class guidance from experienced domain professionals, including industry and technical specialists affiliated with Bayer Healthcare, Qualcomm, Baxter, Pfizer, Genetech, McKesson, Medtronic, CMS, Life Technology, etc.
- Feedback and interaction from a range of stakeholders in the life sciences marketplace
- Notable graduates of the CAP include: Sharklet, Lift Labs, (provide a few big and recognizable names)
- Alumni benefit – Continued access to Larta’s network and resources post program!
Two incubator hubs, CIMIT’s CINTA and NeuroTech Harbor, through the NIH Blueprint MedTech program, are currently seeking proposals from academic and industry applicants who have emerging technologies that aim to improve the diagnosis and/or treatment of nervous system disorders.
A major emphasis of this program is to create opportunities for diverse innovators, including those who have been traditionally underrepresented in the neurotech space.
Program Details:
- Awards up to $500K to help support development toward commercialization.
- Mentorship from experienced commercialization experts
Support to address business, regulatory, clinical, and technical project aspects
Pre-proposals are due no later than October 24th. Learn more and apply: https://blueprintneurotech.org/
[post_title] => Blueprint MedTech Program [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => blueprint-medtech-program [to_ping] => [pinged] => [post_modified] => 2022-12-13 17:03:08 [post_modified_gmt] => 2022-12-13 17:03:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3934 [menu_order] => 18 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 283 [max_num_pages] => 95 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )